Physician profile
Jacqueline Devine
NPI 1578201109
$1,370.17
in general payments reported to CMS, 2019-2025
11 companies · $560 in 2025
The $560 reported for 2025 was more than what 76% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $92.79 · 2023: $353 · 2024: $364 · 2025: $560.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,277.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,277.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $382.73 | 2024-2025 | Airsupra, Breztri, Farxiga |
| Amgen INC. | $366.96 | 2024-2025 | Krystexxa |
| Horizon Therapeutics Plc | $226.85 | 2023 | Krystexxa |
| Lilly USA, LLC | $142.58 | 2023-2025 | Mounjaro, Zepbound |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $81.63 | 2025 | Caplyta |
| Abbvie INC. | $39.99 | 2022 | |
| Merck Sharp & Dohme LLC | $37.97 | 2022 | |
| Exact Sciences Corporation | $32.11 | 2025 | Cologuard Collection Kit |
| Organon LLC | $26.65 | 2025 | Nexplanon |
| Daiichi Sankyo INC. | $17.87 | 2025 | Injectafer |
| Sanofi Pasteur INC. | $14.83 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jacqueline Devine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.